🟢 Rezolute is trading 6% up today after the FDA continued reviewing failed Phase 3 data

Rezolute is trading at $4.29, up +5.67%, rebounding after announcing on September 9, 2026 that the FDA continues reviewing data from its failed Phase 3 sunRIZE study.

• The FDA is evaluating a potential regulatory path for ersodetug, but provided no specific timeline for feedback or next steps.
• The gain is notable as broader markets are lower amid hotter inflation signals.